

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Diabetes

**Manuscript NO:** 62449

**Title:** Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes

**Reviewer's code:** 04010880

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Chief Physician, Associate Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Mexico

**Manuscript submission date:** 2021-01-21

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-01-22 13:31

**Reviewer performed review:** 2021-02-05 15:12

**Review time:** 14 Days and 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

## **SPECIFIC COMMENTS TO AUTHORS**

In this paper, the authors have reviewed the recent progress in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes. Overall, the review is informative and well prepared. I have some suggestions to revise the manuscript.

- Introduction section. It's too long and someone could not focus on the main topic. Please condense the main content and move some content to the subsequent section.
- Page 15. In the section, it has been shown that "TolDC-based phase I clinical trials for the treatment of T1D patients are currently ongoing or have already been completed". However, only one phase I clinical trial was described in the section. It is confusing. Please add the other trials and describe the progress.
- "Perspective obtained from clinical trials with the use of tolDCs for T1D therapy." In order to better describe the current status and prospects of tolDCs for T1D therapy, I suggested that the section be divided into two subsections: i. Clinical trials with good progress but limitations and barriers. ii. Perspectives for T1D therapy.
- Conclusion section should be concise and clear. Please shorten the section.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Diabetes

**Manuscript NO:** 62449

**Title:** Current advances in using tolerogenic dendritic cells as a therapeutic alternative in the treatment of type 1 diabetes

**Reviewer's code:** 02569794

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Thailand

**Author's Country/Territory:** Mexico

**Manuscript submission date:** 2021-01-21

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-01-29 06:31

**Reviewer performed review:** 2021-02-09 03:23

**Review time:** 10 Days and 20 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

The authors did very well on the literature review involving tolerogenic dendritic cells for treatment of autoimmune diabetes mellitus. The manuscript is well written and pictures and table are informative. I have no major concerns about this review manuscript. However, the process of clinical use of cell therapy such as this should be mentioned as well in terms of, for instance, good clinical practicing and relevant instruments that are acceptably used that conform international standards for cell therapy, etc., which will be useful for the audience both scientists and clinicians for the long-term in many aspects including considerations on procedures and expert personnel, management and investment policy related to the laboratory procedure.